[1]胡哲夫,唐其柱,冯一洲,等.IL-6在心血管疾病中的研究进展[J].国际心血管病杂志,2024,01:7-10.
点击复制
IL-6在心血管疾病中的研究进展(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2024年01期
- 页码:
- 7-10
- 栏目:
- 综述
- 出版日期:
- 2024-01-22
文章信息/Info
- Title:
- -
- 作者:
- 胡哲夫; 唐其柱; 冯一洲; 周晨亮
- 430060 武汉大学人民医院心血管内科，代谢与相关慢 病湖北省重点实验室（胡哲夫，唐其柱，冯一洲）；430223 武汉大 学人民医院东院重症医学科（周晨亮）
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2024.01.003
- 文献标识码:
- -
- 摘要:
- 白细胞介素（IL）-6 是固有免疫的关键细胞因子，与免疫防御和调节、细胞增 殖分化等生理功能关系密切。IL-6 与多种心血管疾病相关，如高血压、心力衰竭、心肌病、 心律失常等。该文介绍IL-6 与心血管疾病相关性的研究进展。
- Abstract:
- -
参考文献/References
[1] Coffey S, Roberts-Thomson R, Brown A, et al. Global
epidemiology of valvular heart disease[J]. Nat Rev Cardiol,
2021, 18(12):853-864.
[2] Ridker PM, Rane M. Interleukin-6 signaling and antiinterleukin-
6 therapeutics in cardiovascular disease[J]. Circ Res,
2021, 128(11):1728-1746.
[3] 赵红宇, 李亚山, 朱为梅, 等. caspase-3和caspase-8在铅中毒
大鼠心肌细胞中的表达特点研究[J]. 医学研究杂志, 2020,
49(3):74-79.
[4] Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity:
insights from the interleukin 6 family of cytokines[J]. Immunity,
2019, 50(4):812-831.
[5] Zhang HX, Liu CY, Zhao BM, et al. An evidence-based metaanalysis
on the roles of functional interleukin-6 polymorphisms
in coronary artery disease[J]. J Interferon Cytokine Res, 2018,
38(9):370-377.
[6] 邹光美, 黄朝任. 白介素6基因多态性与多种疾病的相关性研
究[J]. 医学信息, 2022, 35(12):61-64.
[7] Zheng Y, Li YQ, Ran XW, et al. Mettl14 mediates the
inflammatory response of macrophages in atherosclerosis through
the NF-κB/IL-6 signaling pathway[J]. Cell Mol Life Sci, 2022,
79(6):311.
[8] Li JD, Wang TQ, Liu PP, et al. Hesperetin ameliorates hepatic
oxidative stress and inflammation via the PI3K/AKT-Nrf2-ARE
pathway in oleic acid-induced HepG2 cells and a rat model of
high-fat diet-induced NAFLD[J]. Food Funct, 2021, 12(9):3898-
3918.
[9] Rose-John S. Interleukin-6 family cytokines[J]. Cold Spring
Harb Perspect Biol, 2018, 10(2):a028415.
[10] Han F, Li SJ, Yang YK, et al. Interleukin-6 promotes ferroptosis
in bronchial epithelial cells by inducing reactive oxygen speciesdependent
lipid peroxidation and disrupting Iron homeostasis[J].
Bioengineered, 2021, 12(1):5279-5288.
[11] Hoevenaar M, Goossens D, Roorda J. Angiotensin-converting
enzyme 2, the complement system, the kallikrein-kinin system,
type-2 diabetes, interleukin-6, and their interactions regarding the
complex COVID-19 pathophysiological crossroads[J]. J Renin
Angiotensin Aldosterone Syst, 2020, 21(4):1470320320979097.
[12] 谢文博, 李琳. 三碘甲状腺原氨酸、四碘甲状腺原氨酸、白介
素-6和25-羟维生素D与高血压关系的研究进展[J]. 河北医药,
2021, 43(21):3325-3329.
[13] Liu Y, Hou X, Yu M, et al. Clinical analysis of echocardiography
and serum IL-6 and TNF-α changes in pregnant women with
hypertension[J]. Scanning, 2022, 2022:9299746.
[14] Kumar S, Wang G, Zheng N, et al. HIMF (hypoxia-induced
mitogenic factor)-IL (interleukin)-6 signaling mediates
cardiomyocyte-fibroblast crosstalk to promote cardiac
hypertrophy and fibrosis[J]. Hypertension, 2019, 73(5):1058-
1070.
[15] Schaufelberger M. Cardiomyopathy and pregnancy[J]. Heart,
2019, 105(20):1543-1551.
[16] Gregolin CS, do Nascimento M, Borges de Souza SL, et al.
Myocardial dysfunction in cirrhotic cardiomyopathy is associated
with alterations of phospholamban phosphorylation and IL-6
levels[J]. Arch Med Res, 2021, 52(3):284-293.
[17] Scally C, Abbas H, Ahearn T, et al. Myocardial and
systemic inflammation in acute stress-induced (takotsubo)
cardiomyopathy[J]. Circulation, 2019, 139(13):1581-1592.
[18] Wu QF, Liu HX, Liao J, et al. Colchicine prevents atrial
fibrillation promotion by inhibiting IL-1β-induced IL-6 release
and atrial fibrosis in the rat sterile pericarditis model[J]. Biomed
Pharmacother, 2020, 129:110384.
[19] Dobrev D, Aguilar M, Heijman J, et al. Postoperative atrial
fibrillation: mechanisms, manifestations and management[J]. Nat
Rev Cardiol, 2019, 16(7):417-436.
[20] Yao CX, Veleva T, Scott LJ, et al. Enhanced cardiomyocyte
NLRP3 inflammasome signaling promotes atrial fibrillation[J].
Circulation, 2018, 138(20):2227-2242.
[21] Li N, Wang JX, Huo TT, et al. Associations of IL-1β and IL-6
gene polymorphisms with Parkinson's disease[J]. Eur Rev Med
Pharmacol Sci, 2021, 25(2):890-897.
[22] 朱明利, 康品方, 徐庆梅, 等. 活化T细胞核因子4和白介素6
与非瓣膜性心房颤动的相关性研究[J]. 中国心血管病研究,
2021, 19(2):111-116.
[23] Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of lowdose
colchicine after myocardial infarction[J]. N Engl J Med,
2019, 381(26):2497-2505.
[24] Vasques-Nóvoa F, Pedro Ferreira J, Marques P, et al.
Interleukin-6, infection and cardiovascular outcomes in acute
heart failure: findings from the EDIFICA registry[J]. Cytokine,
2022, 160:156053.
[25] Perez AL, Grodin JL, Chaikijurajai T, et al. Interleukin-6 and outcomes in acute heart failure: an ASCEND-HF substudy[J]. J
Card Fail, 2021, 27(6):670-676.
[26] Huo SQ, Shi W, Ma HY, et al. Alleviation of inflammation and
oxidative stress in pressure overload-induced cardiac remodeling
and heart failure via IL-6/STAT3 inhibition by raloxifene[J].
Oxid Med Cell Longev, 2021, 2021:6699054.
[27] 曾清清, 高忠兰, 陈务贤, 等. 高盐诱导高血压大鼠心肌间质重
构及SHIP-1和IL-6的表达研究[J]. 广西医科大学学报, 2023,
40(1):54-58.
[28] Bacchiega BC, Bacchiega AB, Usnayo MJG, et al. Interleukin 6
inhibition and coronary artery disease in a high-risk population: a
prospective community-based clinical study[J]. J Am Heart
Assoc, 2017, 6(3):e005038.
[29] Baker KF, Isaacs JD. Novel therapies for immune-mediated
inflammatory diseases: what can we learn from their use
in rheumatoid arthritis, spondyloarthritis, systemic lupus
erythematosus, psoriasis, Crohn's disease and ulcerative
colitis?[J]. Ann Rheum Dis, 2018, 77(2):175-187.
[30] Traves PG, Murray B, Campigotto F, et al. JAK selectivity and
the implications for clinical inhibition of pharmacodynamic
cytokine signalling by filgotinib, upadacitinib, tofacitinib and
baricitinib[J]. Ann Rheum Dis, 2021, 80(7):865-875.
[31] Baldini C, Moriconi FR, Galimberti S, et al. The JAK-STAT
pathway: an emerging target for cardiovascular disease in
rheumatoid arthritis and myeloproliferative neoplasms[J]. Eur
Heart J, 2021, 42(42):4389-4400.
备注/Memo
- 备注/Memo:
-
基金项目：国家自然科学基金（81700353）；国家重点研发计划
（2018YFC1311300）
通信作者：唐其柱， E-mail：qztang@whu.edu.cn
常用功能
统计/Statistics
- 摘要浏览/Viewed586
- 全文下载/Downloads1721
- 评论/Comments
